The proposed bill, known as the "Doug Cameron Act," establishes a moratorium on the administration of human gene therapy products for infectious disease indications in Idaho. This legislation aims to protect the health and safety of Idaho citizens, particularly in light of adverse effects experienced by individuals, such as Doug Cameron, who suffered severe injuries after receiving a genetic immunization. The bill defines "human gene therapy product" and includes various forms of genetic material and modified organisms, while explicitly excluding products used for cancer treatment or genetic disorders.

The moratorium will remain in effect until July 1, 2035, pending legislative review of safety data. The bill emphasizes the need for caution and oversight in the use of gene therapy products, reflecting the legislature's intent to ensure the well-being of Idahoans. An emergency clause is included, allowing the act to take effect on July 1, 2025.